FDA Approves Johnson & Johnson’s DARZALEX FASPRO as First Treatment for High-Risk Smoldering…
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a single-agent therapy for adults…
Read More...
Read More...
